PD-1 ligand expression in epithelial thyroid cancers. Potential clinical implications
01 Pubblicazione su rivista
Ulisse Salvatore, Tuccilli Chiara, Sorrenti Salvatore, Antonelli Alessandro, Fallahi Poupak, D’Armiento Eleonora, Catania Antonio, Tartaglia Francesco, Amabile Maria Ida, Giacomelli Laura, Metere Alessio, Cornacchini Nicola, Pironi Daniele, Carbotta Giovanni, Vergine Massimo, Monti Massimo, Baldini Enke
DOI: 10.3390/ijms20061405
ISSN: 1661-6596
The new immunotherapy targeting the programmed cell death 1 (PD-1) receptor and its cognate ligand PD-L1 has renewed hopes of eradicating the most difficult human cancers to treat. Among these, there are the poorly differentiated and anaplastic thyroid cancers, unresponsive to all the therapies currently in use. In the present review we will summarize information regarding the expression of PD-L1 in the different thyroid cancer histotypes, its correlation with clinicopathological features, and its potential prognostic value. Then, we will evaluate the available data indicating the PD-1/PD-L1 axis as a promising target for thyroid cancer therapy.